Overview

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Status:
Recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

This study is phase II, open label, clinical trial to determine the efficacy of Niraparib re-treatment with Bevacizumab of assessment progression-free survival(6 months PFS rate) with platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor.

Phase:

Phase 2

Details

Lead Sponsor:

Yonsei University

Collaborator:

Takeda

Treatments:

Bevacizumab
Niraparib